Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice

Blood (2024) 143 (21): 2201–2216.

https://doi.org/10.1182/blood.2023023549

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment- Sensitive, Dependent, and Refractory Chronic Gvhd: Incidence and Clinical Outcomes

Shannon Herzog, Ryan Shanley, Shernan G. Holtan, Margaret L. MacMillan, Daniel Weisdorf, Najla H El Jurdi

Blood (2023) 142 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2023-178693

Published: 2023

Journal Articles

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Karamjeet S. Sandhu, John Altin, Tao Wang, Jakob Devos, Medhat Askar, Zachariah DeFilipp, Ketevan Gendzekhadze, Carrie L. Kitko, Stephanie J. Lee, Margaret L. MacMillan, Stephen R. Spellman, Ryotaro Nakamura

Blood (2023) 142 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2023-186724

Published: 2023

Journal Articles

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Nosha Farhadfar, Zeina Al-Mansour, Tao Wang, Karen Chen, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephen R. Spellman, John R. Wingard, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 5108–5109.

https://doi.org/10.1182/blood-2022-163537

Published: 2022

Journal Articles

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Caden Ulschmid, Xiao Li, Tao Wang, Brent Logan, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephanie J. Lee, Stephen R. Spellman, Wael Saber

Blood (2022) 140 (Supplement 1): 279–281.

https://doi.org/10.1182/blood-2022-163263

Published: 2022

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes

Shannon Herzog, Daniel J. Weisdorf, Ryan Shanley, Margaret L. MacMillan, Shernan G Holtan, Najla El Jurdi

Blood (2022) 140 (Supplement 1): 10493–10494.

https://doi.org/10.1182/blood-2022-158814

Published: 2022

Journal Articles

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Asim Saha, Sharon Hyzy, Tahirih Lamothe, Katelyn Hammond, Nicholas Clark, Leanne Lanieri, Prashant Bhattarai, Rahul Palchaudhuri, Geoffrey O. Gillard, Jennifer Proctor, Megan J. Riddle, Angela Panoskaltsis-Mortari, Margaret L. MacMillan, John E. Wagner, Hans-Peter Kiem, Lisa M. Olson, Bruce R. Blazar

Blood (2022) 139 (11): 1743–1759.

https://doi.org/10.1182/blood.2021012366

Published: 2022

Includes: Supplemental data

Journal Articles

Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials

Michael A. Pratta, Najla H El Jurdi, Armin Rashidi, Brian C. Betts, John P Galvin, Margaret L. MacMillan, Daniel J. Weisdorf, Angela Panoskaltsis-Mortari, Shernan G Holtan

Blood (2021) 138 (Supplement 1): 259.

https://doi.org/10.1182/blood-2021-150867

Published: 2021

Journal Articles

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Blood (2021) 138 (Supplement 1): 261.

https://doi.org/10.1182/blood-2021-145008

Published: 2021

Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Blood (2021) 138 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2021-147569

Published: 2021

Journal Articles

Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?

Whitney Wallis, Alison Gulbis, Tao Wang, Karen Chen, Carrie Lynn Kitko, Margaret L. MacMillan, Joseph Pidala, Marcie L. Riches, Stephen R. Spellman, Mukta Arora, Amin M. Alousi

Blood (2021) 138 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2021-148890

Published: 2021

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Parth Gandhi, Isha Gandhi, Andrea Hoeschen, Wes Mosher, Margaret L. MacMillan, MD, Armin Rashidi, MD PhD, Najla H El Jurdi, MD, Alexander Khoruts, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Qing Cao, MS, Brian C. Betts, MD, Angela Panoskaltsis-Mortari, PhD, Chi Chen, Shernan G Holtan, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140117

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Caitlin W Elgarten, MD MSc, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Richard Aplenc, MD PhD, Michael T. Hemmer, MS, Mukta Arora, MD, Stephen R. Spellman, MS, Tao Wang, PhD, Madan Jagasia, MBBS, MS, MMHC, Margaret L. MacMillan, MD, Joseph Pidala, MD, Brian T. Fisher, DO, MSCE, Matt Hall, PhD

Blood (2019) 134 (Supplement_1): 599.

https://doi.org/10.1182/blood-2019-130466

Published: 2019

Journal Articles

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Shernan Holtan, MD, Todd E. DeFor, MS, Armin Rashidi, MD PhD, Alexander Khoruts, MD, Christopher Staley, PhD, Lucie M Turcotte, MD, Pamala A. Jacobson, PharmD, Daniel J. Weisdorf, MD, Margaret L. MacMillan, MD

Blood (2019) 134 (Supplement_1): 39.

https://doi.org/10.1182/blood-2019-129236

Published: 2019

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival

Sarah L.P. Atkins, MD, Todd E. DeFor, MS, Margaret L. MacMillan, MD, Lucie Turcotte, MD, Armin Rashidi, MD PhD, Daniel J. Weisdorf, MD, Alexander Khoruts, MD, Shernan G. Holtan, MD

Blood (2018) 132 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2018-99-115686

Published: 2018

NARROW

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice

Treatment- Sensitive, Dependent, and Refractory Chronic Gvhd: Incidence and Clinical Outcomes

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only